Avalyn Pharma appointed Robert Meyer, M.D. as an independent Class II director and made him eligible for a $40,000 annual retainer. Meyer also received an option to buy 31,182 common shares, while his regulatory and life-sciences experience adds specialized expertise to the board’s oversight of drug-development matters.

Key Highlights

  • Robert Meyer received an option to purchase 31,182 shares of Avalyn Pharma common stock.
  • Meyer previously held senior regulatory roles at the FDA and Merck Research Laboratories.
  • The compensation policy provides eligible continuing directors with annual Options for 15,591 common shares.

Avalyn Pharma Inc. (NASDAQ: AVLN) appointed Robert Meyer, M.D. As an independent Class II director, making him eligible for a $40,000 annual retainer. The board selected Meyer following a recommendation from its Nominating and Corporate Governance Committee.

31,182-Share Initial Option Grant

Meyer received an option to purchase 31,182 shares of Avalyn Pharma common stock, which has a Par Value of $0.001 per share. The grant vests in equal annual installments under its stated vesting schedule, and its exercise price is set at the common stock’s fair Market Value on the grant date. Meyer will also be eligible for an annual option grant covering 15,591 common shares while he remains a director. His first annual grant will be prorated monthly based on his service, while grants to continuing non-employee directors vest under the compensation policy’s annual meeting terms.

Regulatory and Board Experience

Avalyn Pharma cited Meyer’s experience advising on drug-approval matters, serving on public life-sciences company boards and practicing medicine as qualifications for the appointment. He also signed an indemnification agreement consistent with those used for the company’s existing non-employee directors.